Diagnosis and Treatment of Cystic Fibrosis: A (Not-so) Simple Recessive Condition

[1]  The National Society of Genetic Counselors.  National Society of Genetic Counselors Code of Ethics , 2018, Journal of Genetic Counseling.

[2]  K. Southern,et al.  Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease. , 2017, Paediatric respiratory reviews.

[3]  S. McColley,et al.  Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del‐CFTR , 2017, Annals of the American Thoracic Society.

[4]  L. Hercher,et al.  Attitudes Toward Discussing Approved and Investigational Treatments for Cystic Fibrosis in Prenatal Genetic Counseling Practice , 2017, Journal of Genetic Counseling.

[5]  D. Bedwell,et al.  Discovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations. , 2016, American journal of respiratory and critical care medicine.

[6]  K. Kirk,et al.  Analysis of cystic fibrosis-associated P67L CFTR illustrates barriers to personalized therapeutics for orphan diseases. , 2016, JCI insight.

[7]  M. Rosenfeld,et al.  Cystic Fibrosis Diagnosis and Newborn Screening. , 2016, Pediatric clinics of North America.

[8]  M. Amaral,et al.  Progress in therapies for cystic fibrosis. , 2016, The Lancet. Respiratory medicine.

[9]  S. Pierandrei,et al.  The Impact on Genetic Testing of Mutational Patterns of CFTR Gene in Different Clinical Macrocategories of Cystic Fibrosis. , 2016, The Journal of molecular diagnostics : JMD.

[10]  S. Rowe,et al.  197 Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D-CTFR mutation: data from the ENVISION study , 2016 .

[11]  S. McColley,et al.  Refining the continuum of CFTR‐associated disorders in the era of newborn screening , 2016, Clinical genetics.

[12]  Garry R. Cutting,et al.  From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations , 2016, Molecular biology of the cell.

[13]  A. Quittner,et al.  Parental Depression and Pancreatic Enzymes Adherence in Children With Cystic Fibrosis , 2016, Pediatrics.

[14]  M. Pearl,et al.  Newborn Screening for Cystic Fibrosis in California , 2015, Pediatrics.

[15]  S. McColley.  Sorting out the gray zone: Cystic fibrosis newborn screening. , 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[16]  N. Derichs,et al.  Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID): A new designation and management recommendations for infants with an inconclusive diagnosis following newborn screening. , 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[17]  D. Borowitz.  CFTR, bicarbonate, and the pathophysiology of cystic fibrosis , 2015, Pediatric pulmonology.

[18]  C. Bear,et al.  Facilitating Structure-Function Studies of CFTR Modulator Sites with Efficiencies in Mutagenesis and Functional Screening , 2015, Journal of biomolecular screening.

[19]  F. Gage,et al.  Functional Gene Correction for Cystic Fibrosis in Lung Epithelial Cells Generated from Patient iPSCs. , 2015, Cell reports.

[20]  Norma P. Tavakoli,et al.  Utility of a very high IRT/No mutation referral category in cystic fibrosis newborn screening , 2015, Pediatric pulmonology.

[21]  D. Waltz,et al.  WS01.3 Lumacaftor in combination with ivacaftor in patients with cystic fibrosis who are homozygous for the F508del-CFTR mutation , 2015 .

[22]  C. Thauvin-Robinet,et al.  WS11.6 Newborn screening for cystic fibrosis: Rationale for p.Arg117His (R117H) removal from the CFTR mutation panel in France , 2015 .

[23]  D. Sanders,et al.  Outcomes of Infants With Indeterminate Diagnosis Detected by Cystic Fibrosis Newborn Screening , 2015, Pediatrics.

[24]  B. Ramsey,et al.  Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  Garry R. Cutting,et al.  Cystic fibrosis genetics: from molecular understanding to clinical application , 2014, Nature Reviews Genetics.

[26]  Umer Khan,et al.  Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. , 2014, American journal of respiratory and critical care medicine.

[27]  K. De Boeck,et al.  The relative frequency of CFTR mutation classes in European patients with cystic fibrosis. , 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[28]  W. Grody,et al.  Carrier screening for cystic fibrosis in the new era of medications that restore CFTR function , 2014, The Lancet.

[29]  J. Clancy,et al.  Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data. , 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[30]  Kathryn E. Singh,et al.  Diagnosis of cystic fibrosis in the kindred of an infant with CFTR‐related metabolic syndrome: Importance of follow‐up that includes monitoring sweat chloride concentrations over time , 2014, Pediatric pulmonology.

[31]  Roger L. Brown,et al.  Long-term follow-up of cystic fibrosis newborn screening: psychosocial functioning of adolescents and young adults. , 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[32]  S. Keiles,et al.  Molecular Testing for Cystic Fibrosis Carrier Status Practice Guidelines: Recommendations of the National Society of Genetic Counselors , 2014, Journal of Genetic Counseling.

[33]  S. Rowe,et al.  Understanding the relationship between sweat chloride and lung function in cystic fibrosis. , 2013, Chest.

[34]  George P Patrinos,et al.  Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene , 2013, Nature Genetics.

[35]  S. Colley,et al.  WS7.4 Lumacaftor, an investigational CFTR corrector, in combination with ivacaftor, a CFTR potentiator, in CF patients with the F508del-CFTR mutation: Phase 2 interim analysis , 2013 .

[36]  R. Sebro,et al.  Cystic fibrosis mutations for p.F508del compound heterozygotes predict sweat chloride levels and pancreatic sufficiency , 2012, Clinical genetics.

[37]  C. Greene,et al.  Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology , 2013, International journal of nanomedicine.

[38]  B. Burton,et al.  WS14.1 Ivacaftor potentiates mutant CFTR forms associated with residual CFTR function , 2012 .

[39]  F. van Goor,et al.  Ivacaftor potentiation of multiple CFTR channels with gating mutations. , 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[40]  D. Sanders,et al.  Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies. , 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[41]  Roger L. Brown,et al.  Factors associated with parental perception of child vulnerability 12 months after abnormal newborn screening results. , 2011, Research in nursing & health.

[42]  P. Farrell,et al.  Optimal DNA tier for the IRT/DNA algorithm determined by CFTR mutation results over 14 years of newborn screening. , 2011, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[43]  B. Kerem,et al.  Recommendations for the classification of diseases as CFTR-related disorders. , 2011, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[44]  A. Tluczek,et al.  A Tailored Approach to Family-Centered Genetic Counseling for Cystic Fibrosis Newborn Screening: The Wisconsin Model , 2011, Journal of Genetic Counseling.

[45]  Judith M Ayala,et al.  Parental response to a diagnosis of diabetes: how nurses can help. , 2011, Journal of pediatric nursing.

[46]  A. Quittner,et al.  Depressive symptoms in children with cystic fibrosis and parents and its effects on adherence to airway clearance , 2010, Pediatric pulmonology.

[47]  Antonia Zapf,et al.  Intestinal current measurement for diagnostic classification of patients with questionable cystic fibrosis: validation and reference data , 2010, Thorax.

[48]  A. Hamosh,et al.  False Negative Cystic Fibrosis Newborn Screen , 2010, Clinical pediatrics.

[49]  M. Rosenfeld,et al.  Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond. , 2009, The Journal of pediatrics.

[50]  G. Kieckhefer,et al.  Managing childhood chronic illness: parent perspectives and implications for parent-provider relationships. , 2009, Families, systems & health : the journal of collaborative family healthcare.

[51]  M. Rosenfeld,et al.  Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. , 2009, The Journal of pediatrics.

[52]  Vicky A Legrys,et al.  Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. , 2008, The Journal of pediatrics.

[53]  G. Lancaster,et al.  Parental depression following the early diagnosis of cystic fibrosis: a matched, prospective study. , 2007, The Journal of pediatrics.

[54]  C. Goss,et al.  CFTR genotype as a predictor of prognosis in cystic fibrosis. , 2006, Chest.

[55]  R. Bennett,et al.  A New Definition of Genetic Counseling: National Society of Genetic Counselors’ Task Force Report , 2006, Journal of Genetic Counseling.

[56]  W. Hwang,et al.  Feasibility and preliminary outcomes from a pilot study of a brief psychological intervention for families of children newly diagnosed with cancer. , 2005, Journal of pediatric psychology.

[57]  Victoria M. Pratt,et al.  Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel , 2004, Genetics in Medicine.

[58]  Michael R Knowles,et al.  Basic protocol for transepithelial nasal potential difference measurements. , 2004, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[59]  R. Parad,et al.  Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections. , 2004, Pediatrics.

[60]  T. Campbell.  The effectiveness of family interventions for physical disorders. , 2003, Journal of marital and family therapy.

[61]  Elizabeth A. Carter,et al.  The Expanded Family Life Cycle: Individual, Family, and Social Perspectives , 1998 .

[62]  L. Tsui,et al.  A mutation in CFTR produces different phenotypes depending on chromosomal background , 1993, Nature Genetics.

[63]  J. Riordan,et al.  Identification of the Cystic Fibrosis Gene : Chromosome Walking and Jumping Author ( s ) : , 2008 .

[64]  L. Tsui,et al.  Erratum: Identification of the Cystic Fibrosis Gene: Genetic Analysis , 1989, Science.

[65]  F. van Goor,et al.  Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor. , 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[66]  E. Alton,et al.  Cystic Fibrosis Gene Therapy – Not Low-hanging Fruit , 2016 .

[67]  M. Brennan,et al.  Cystic Fibrosis: A Review of Associated Phenotypes, Use of Molecular Diagnostic Approaches, Genetic Characteristics, Progress, and Dilemmas. , 2016, The Journal of molecular diagnostics : JMD.

[68]  F. van Goor,et al.  Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. , 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[69]  ACOG Committee Opinion No. 486: Update on carrier screening for cystic fibrosis. , 2011, Obstetrics and gynecology.

[70]  B. Kerem,et al.  Nonsense-mediated mRNA decay and cystic fibrosis. , 2011, Methods in molecular biology.

[71]  L. Saiman,et al.  Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy. , 2010, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[72]  M. Kosorok,et al.  Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. , 2001, Pediatrics.

[73]  L. Tsui,et al.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. , 1989, Science.

[74]  L. Tsui,et al.  Identification of the cystic fibrosis gene: genetic analysis. , 1989, Science.